首页> 美国卫生研究院文献>other >First-Line Anti-Tubercular Drug Resistance of Mycobacterium tuberculosis in IRAN: A Systematic Review
【2h】

First-Line Anti-Tubercular Drug Resistance of Mycobacterium tuberculosis in IRAN: A Systematic Review

机译:伊朗结核分枝杆菌的一线抗结核药物耐药性:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: The spread of drug-resistant tuberculosis (TB) is one of the major public health problems through the world. Surveillance of anti-TB drug resistance is essential for monitoring of TB control strategies. The occurrence of drug resistance, particularly multi-drug resistance Mycobacterium tuberculosis (MDR), defined as resistance to at least rifampicin (RIF) and isoniazid (INH), has become a significant public health dilemma. The status of drug-resistance TB in Iran, one of the eastern Mediterranean countries locating between Azerbaijan and Armenia and high-TB burden countries (such as Afghanistan and Pakistan) has been reported inconsistently. Therefore, the aim of this study was to summarize reports of first-line anti-tubercular drug resistance in M. tuberculosis in Iran.>Material and Methods: We systematically reviewed published studies on drug-resistant M. tuberculosis in Iran. The search terms were “Mycobacterium tuberculosis susceptibility” or “Mycobacterium tuberculosis resistant” and Iran.>Results: Fifty-two eligible articles, published during 1998–2014, were included in this review. Most of the studies were conducted in Tehran. The most common used laboratory method for detecting M. tuberculosis drug resistant was Agar proportion. The highest resistance to first-line drugs was seen in Tehran, the capital city of Iran. The average prevalence of isoniazid (INH), rifampin (RIF), streptomycin (SM), and ethambotol (EMB) resistance via Agar proportion method in Tehran was 26, 23, 22.5, and 16%, respectively. In general, resistance to INH was more common than RIF, SM, and EMB in Tehran>Conclusions: In conclusion, this systematic review summarized the prevalence and distribution of first-line anti-tubercular drug resistance of M. tuberculosis in Iran. Our results suggested that effective strategies to minimize the acquired drug resistance, to control the transmission of resistance and improve the diagnosis measures for TB control in Iran.
机译:>背景:耐药结核病的传播是全世界主要的公共卫生问题之一。监测抗结核药物耐药性对于监测结核病控制策略至关重要。耐药性的发生,特别是多重耐药性的结核分枝杆菌(MDR),被定义为至少对利福平(RIF)和异烟肼(INH)具有耐药性,已经成为一个重大的公共卫生难题。据报道,伊朗是位于阿塞拜疆和亚美尼亚之间的东部地中海国家之一以及高结核病负担国家(例如阿富汗和巴基斯坦)的耐药结核病的状况。因此,本研究旨在总结伊朗结核分枝杆菌一线抗结核药物耐药性的报道。>材料与方法:我们系统地综述了已发表的关于耐药结核分枝杆菌的研究在伊朗。检索词为“结核分枝杆菌易感性”或“抗结核分枝杆菌”。>结果: 1998-2014年间发表的52篇合格文章被纳入本评价。大多数研究在德黑兰进行。用于检测结核分枝杆菌耐药性的最常用实验室方法是琼脂比例。一线药物的抵抗力最高的是伊朗首都德黑兰。通过琼脂比例法,在德黑兰,异烟肼(INH),利福平(RIF),链霉素(SM)和乙丹酚(EMB)耐药的平均发生率分别为26%,23%,22.5%和16%。总的来说,在德黑兰,对INH的耐药性比RIF,SM和EMB更为常见。结论:总之,本系统综述总结了M一线抗结核药耐药性的流行和分布。伊朗的结核病。我们的结果表明,有效的策略应尽量减少获得性耐药性,控制耐药性的传播并改善伊朗结核病控制的诊断措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号